Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. - Wikidata - wikimedia - TriplyDB

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

http://www.wikidata.org/entity/Q34519193

about

Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention Use of rifaximin in gastrointestinal and liver diseases Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications President's address: travel medicine and principles of safe travel Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico Pathophysiology and impact of enteric bacterial and protozoal infections: new approaches to therapy.Bile acids improve the antimicrobial effect of rifaximin.Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study.Travelers' diarrhea: antimicrobial therapy and chemoprevention.In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008 Therapy of travelers' diarrhea with rifaximin on various continents.Rifaximin pharmacology and clinical implications.Prevention and self-treatment of traveler's diarrhea.Expert review of the evidence base for prevention of travelers' diarrhea.Expert review of the evidence base for self-therapy of travelers' diarrhea.Rifaximin for the treatment of acute infectious diarrhea Management of infectious diarrhoea Antibiotics for the treatment of irritable bowel syndrome Enteroaggregative Escherichia coli: an emerging enteric pathogen.Review article: the antimicrobial effects of rifaximin on the gut microbiota.Rifaximin: a new treatment for travelers' diarrhea.Rifaximin in the treatment of infectious diarrhea.Management of diverticular disease: is there room for rifaximin?Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents.Current and future developments in travelers' diarrhea therapy.Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.Enterotoxigenic Escherichia coli (ETEC): a recurring decimal in infants' and travelers' diarrhea.The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.Rifaximin therapy of irritable bowel syndrome.Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.Biologic properties and clinical uses of rifaximin.Rifaximin: recent advances in gastroenterology and hepatology Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.Rifaximin: beyond the traditional antibiotic activity.Antimicrobial prevention and therapy for travelers' infection.Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

P2860

Q24530558-5EB6AD8A-FC12-4BB9-9EF0-EE364DF71B78 Q26740201-AC877F89-7C05-45E4-99ED-1FC82B0572E7 Q26775927-E1011225-0623-4102-B745-23A33D25723B Q28384463-64DDE9EF-097D-4D72-B235-78CEC8C9B011 Q28387005-0A2EF591-9FB1-40A7-BDC9-69C6C8639BC2 Q28395207-456E1C7A-76B3-47D4-BDB2-52F267FCD12A Q30436681-C6E68906-F13C-474C-8B6D-6B34CE189704 Q34108534-191D99F4-812A-4A9F-B0AB-D8EF30779E19 Q34206683-6A40908C-31C3-4FFD-8B0D-4F19E15C6A69 Q34464671-341EC4AD-C52A-4684-87BE-EA46DFBC5482 Q34529094-AF531C60-B725-4426-BE32-BAA2BEC07AE7 Q34534555-58E161E5-81A6-40A6-9C83-BCDFF7BD7D88 Q34607677-F41610BB-7BD3-48FD-BB4A-89A3C5413D2A Q34974972-A443D2D0-0F07-465E-AA43-FFDA53D0E385 Q34987670-A8B8E18B-FCE8-4023-8907-DD0674839418 Q34987675-44CC6554-CADB-45BE-A4F7-79DF873F1618 Q35090413-AD5CD689-35C6-419C-9B99-57C02F0BCDF8 Q35598312-200E4E8D-4858-4909-A6DE-C6D387CEABF4 Q35691133-FA29B888-3341-405C-B823-6300B5535394 Q35716649-0AD1AC7C-27C5-4BD1-B431-A4C83B86411F Q35855732-09B1C6AC-E0F3-463E-AC6A-18027FFDD7A5 Q35983943-FE5A80B7-B0BB-468C-A115-3BA90B12091E Q36108487-5FB56340-72B8-4EA4-BCA5-676DD8C4AC31 Q36108507-6D6BB3AC-3917-4BAC-9E64-A155C614CE4E Q36140657-F1EB176D-1BED-421C-AF1B-418B154B2D11 Q36404962-15B1EACC-9E43-4FDE-9F1A-A3C889A951A0 Q36505498-73CBEA8C-1C99-43CA-B90C-32B1DF5A6D67 Q36533648-47A845EE-E7F4-4EB1-829B-AF140578CC24 Q37026639-7BA62AE3-AA78-49C5-8B5D-11622250DDAD Q37258500-ECFC8D9F-D7E5-4357-9104-069980B942AF Q37412963-6B34ECA4-EFC6-4C32-9285-E89FEF3E4139 Q37678916-2E947A2C-1707-4CB7-BBE7-75F009790E48 Q37704526-D0600C5A-272E-4791-AD0A-75457FC71853 Q37768415-B835B81C-7C6F-49D5-BB08-3AD3FC85F8A0 Q37827877-175F10B5-5E97-4487-A796-F867128D7A98 Q38074951-BC74E6D5-20BD-497A-A8CB-410A675019AF Q38078988-A74C1E30-414D-4874-8EBD-C26397BB7D66 Q38237218-BCE5F47A-C741-4D4E-B914-8862E4D61B35 Q38573032-5AEB76E3-2CB2-4DAC-A596-9634E083C5A5 Q38682282-E5831458-8D5E-443B-9423-0DBE143721E5

P2860

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

http://www.wikidata.org/entity/Q34519193

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@ast

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@en

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@nl

type

label

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@ast

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@en

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@nl

prefLabel

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@ast

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@en

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@nl

P1433

Q34519193-A419EB3A-751F-4F89-A42D-D7B32D36F82C

P1476

Q34519193-D865B8B4-4607-4A6F-8BF2-7C0D5CFE24DC

P2093

Q34519193-0ED5D690-94C5-42CE-897B-AB76B019D6B9

Q34519193-24787761-C8AB-4672-8113-8026D3CAA091

Q34519193-3EE577D4-B8F4-49B2-A86D-29030012D0F5

Q34519193-3FB7335A-FDC3-4A5E-AB8C-745B2AE7124D

Q34519193-63698F96-5974-48BE-885E-F4598F41A4A9

Q34519193-AAD6B604-D60A-4DE9-BF09-D6E3746BB430

Q34519193-B0F341CA-BCFE-4BA7-9018-8FD36A47C752

Q34519193-B673A710-8830-44BB-85F4-7304C8813A0F

Q34519193-C18DD522-D588-44EF-A809-286881985005

Q34519193-D44083FC-908F-4E7D-85C6-40E153DB679D

P2860

Q34519193-187A7474-E37E-4BAE-A0B7-071F93E8F466

Q34519193-42925978-61D8-4AE9-B231-1E514A9BDE71

Q34519193-4B156B4A-7D22-4655-9E81-B1E6E0DA260F

Q34519193-5C01DAF2-D4BE-42F1-A233-8BE50C66BDB0

Q34519193-646084B7-A754-47D7-B07B-49D149307B46

Q34519193-679417EF-17FD-4B01-863F-0CEAD716A289

Q34519193-6E8F109B-383F-4B07-B9CB-4B8AD55D98A6

Q34519193-71066647-014C-4D97-B0D2-4FC1A7068D10

Q34519193-78255E38-C4F3-4DDE-83C7-4FAB8CE5AD8B

Q34519193-962F750C-E6A3-4933-A654-0BFBD822AB66

P304

Q34519193-F8723558-DD9A-4395-A5CD-1D557B571999

P31

Q34519193-472B5BDB-E1BC-470B-8C0A-85CBC413D32F

P356

Q34519193-29C53B52-1234-495F-8FD6-ED28619A1DA7

P407

Q34519193-2AB064C9-90C3-44CD-BCCE-E719605F63F7

P433

Q34519193-59FDA94D-FDE6-43A9-B0F2-E96292D5D616

P478

Q34519193-ACC8A042-E109-4A32-BF7A-78FE2FEAF1FD

P577

Q34519193-E3E0CBAC-250B-4807-80B9-8A5C2089B42E

P5875

Q34519193-F1606724-42C8-4F38-A3C4-0F273F67845F

P698

Q34519193-A62BDA05-A246-4131-8CF8-07B828DCE7A3

P921

Q34519193-CDCBC2A3-84E0-4C82-B70D-51922CEB99D3

P356

P1433

Clinical Infectious Diseases

P1476

Rifaximin versus ciprofloxacin ...... , double-blind clinical trial.

@en

P2093

C D Ericsson

http://www.w3.org/2001/XMLSchema#string

D Ashley

http://www.w3.org/2001/XMLSchema#string

E Palazzini

http://www.w3.org/2001/XMLSchema#string

F Martinez-Sandoval

http://www.w3.org/2001/XMLSchema#string

H L DuPont

http://www.w3.org/2001/XMLSchema#string

J A Adachi

http://www.w3.org/2001/XMLSchema#string

J J Mathewson

http://www.w3.org/2001/XMLSchema#string

L M Riopel

http://www.w3.org/2001/XMLSchema#string

M W DuPont

http://www.w3.org/2001/XMLSchema#string

Z D Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Enteroaggregative Escherichia coli.

In vitro activity and fecal concentration of rifaximin after oral administration

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial.

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea.

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.

Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study

How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma.

Travelers' diarrhea and toxigenic Escherichia coli.

P304

1807-1815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/323814

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11662470

http://www.w3.org/2001/XMLSchema#string

P698

11692292

http://www.w3.org/2001/XMLSchema#string

P921

Afọ ọsịsa